News
Kernel is advancing precision neuromedicine - Q1 2024 update
February 9, 2024
In the last year we launched Kernel Flow2, shipped our first systems to researchers, published validation work from Flow1, started to build brain-based biomarkers for depression and mild cognitive impairment, completed a number of partnerships to help companies developing products for the brain (not just pharmaceuticals), and refreshed our brand.
Kernel Launches Observational Study Using Flow2 Neuroimaging Technology to Identify Biomarkers of Depression Treatment Response
August 29, 2023
The study utilizes Flow2 to measure patients as they undergo treatment, paving the way to transform how depression is treated with patient-specific biomarkers.
Kernel Launches Cognitive Decline Study Using Flow2 Neuroimaging Technology
August 21, 2023
By leveraging the advanced capabilities of the Flow2 neuroimaging technology, this groundbreaking study aims to detect Mild Cognitive Impairment (MCI) and measure the severity of MCI symptoms by analyzing Flow2 neurophysiological data obtained during a battery of cognitive tasks and resting state measures.
Kernel Introduces Flow2: Revolutionary Advanced Neuroimaging Technology Enabling Precision Neuromedicine
July 31, 2023
With Flow2, researchers and clinicians now have unprecedented access to robust, fMRI-like functional neuroimaging in a quick and user-friendly headset, making precision neuromedicine more accessible than ever before.
Kernel's Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic Effects
July 20, 2023
The peer-reviewed study, sponsored by Cybin Inc., underscores the ability of Kernel's Flow1 system to capture and analyze brain changes resulting from the administration of a psychoactive substance.
Kernel Flow1 Differentiates Alcohol Doses using Brain Measurements
June 26, 2023
This peer-reviewed study demonstrates the ability of the Kernel Flow1 neuroimaging system to measure dose-dependent brain responses to alcohol.
Featured In